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Christopher L. Antonacci3, Joseph Mendelis2, Alexander R. Vaccaro2,3,  
D. Greg Anderson2,3, Chris K. Kepler2,3
1Hackensack University Medical Center, Hackensack, NJ, USA  
2Thomas Jefferson University, Department of Orthopedic Surgery, Philadelphia, PA, USA  
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Objective: To determine if there is correlation between intradiscal levels of interleukin-6 
(IL-6) and early outcome measures in patients undergoing lumbar fusion for painful disc 
degeneration.
Methods: Intervertebral disc tissue was separated into annulus fibrosus/nucleus pulposus 
and cultured separately in vitro in serum-free medium (Opti-MEM). Conditioned media 
was collected after 48 hours. The concentration of IL-6 was quantified using enzyme-linked 
immunosorbent assay. Pearson correlation coefficients quantified relationships between 
IL-6 levels and pre- and postoperative visual analogue scale (VAS) back pain and Oswestry 
Disability Index (ODI), as well as change in VAS/ODI.
Results: Sixteen discs were harvested from 9 patients undergoing anterior lumbar interbody 
fusion (mean age, 47.4 years; range, 21–70 years). Mean preoperative and 6-month post-
operative VAS were 8.1 and 3.7, respectively. Mean preoperative and postoperative ODI 
were 56.2 and 25.6, respectively. There were significant positive correlations between IL-6 
expression and postoperative VAS (ρ = 0.38, p = 0.048) and ODI (ρ = 0.44, p = 0.02). No 
significant correlations were found between intradiscal IL-6 expression and preoperative VAS 
(ρ = -0.12, p = 0.54). Trends were seen associating IL-6 expression and change in VAS/ODI 
(ρ = -0.35 p = 0.067; ρ = -0.34, p = 0.08, respectively). A trend associated IL-6 and preop-
erative ODI (ρ = 0.36, p = 0.063).
Conclusion: The direct association between IL-6 expression and VAS/ODI suggests patients 
with elevated intradiscal cytokine expression may have worse early outcomes than those 
with lower expression of IL-6 after surgery for symptomatic disc degeneration.
Keywords: Lumbar, Disc, Degeneration, Cytokine, Interleukin-6
INTRODUCTION
Lumbar disc degeneration is a significant contributor to low 
back pain,1,2 accounting for almost 10% of lumbar fusion sur-
gery performed in the United States.3 Despite extensive study of 
the degenerative process in the disc, the exact cause for disco-
genic back pain has not been elucidated. Compounding the dif-
ficulty in understanding this condition is the fact that only a mi-
nority of those with degenerative changes are affected by severe, 
chronic back pain.4
Despite the high incidence of surgery for painful disc degen-
eration, there are no highly accurate testing strategies to con-
firm the presence of pain at a particular disc level and the re-
sults of this type of surgery remain suboptimal. Provocative 
discography, which has been widely used, has been shown to 
have the potential for false-positive results.5,6 Magnetic reso-
nance imaging (MRI) studies, which are quite sensitive to de-
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search on the molecular basis of degenerative disc disease has 
greatly increased our insight into the biology underlying this 
complex process. In recent years, the role of specific molecules 
including cytokines and enzymes which degrade the interverte-
bral disc (IVD) extracellular matrix has become more clear.7 In 
addition, expression levels of systemic inflammatory mediators 
(tumor necrosis factor [TNF]-α, sTNF-R1, interleukin [IL]-1β, 
and IL-6) have been studied with respect to the incidence of 
acute low back pain.8 Associations were found between IL-6 
and qualities of pain when combined with depressive symp-
toms, as well as TNF-α with pain severity and disability when 
combined with several other factors.8 In fact, intradiscal injec-
tions of antibodies to IL-6 have recently been studied for the 
treatment of low back pain with promising short-term results,9 
with mixed results seen for TNF-α inhibitors.10,11 In another 
earlier study comparing disc tissue from patients undergoing 
fusion or discectomy, there were significantly higher levels of 
IL-6 and IL-8 in the fusion group, suggesting that these play a 
role in painful disc degeneration.12
It is possible that the intradiscal concentration of IL-6 in pa-
tients with chronic low back pain may correlate with functional 
outcomes before and after surgery. A clearer understanding of 
this potential relationship may help predict which patients will 
have better or worse outcomes in the postoperative period. Pre-
vious work has shown that certain cytokines are more highly 
expressed in painful disc tissue versus nonpainful disc tissue13 
but correlation with clinical outcome following surgery has nev-
er been studied. The goal of this study is to identify the associa-
tion, if any exists, between the intradiscal IL-6 concentration at 
a particular disc level and clinical outcome before and after lum-
bar fusion surgery. We hypothesize that there will be a positive 
correlation between the levels of expressed IL-6 and the degree 
of improvement in pain and disability as measured by visual 
analogue scale (VAS) and Oswestry Disability Index (ODI).
MATERIALS AND METHODS
This study was approval by the Institutional Review Board 
(IRB) of Jefferson University (IRB No. 08D.525). Patients with 
severe discogenic low back pain recalcitrant to nonsurgical 
management were recruited for study participation according 
to specific inclusion and exclusion criteria. Adult patients (>18 
years) scheduled to undergo anterior lumbar interbody fusion 
(ALIF) for painful lumbar disc degeneration were included. All 
patients had a positive preoperative discogram (≥ 7/10) at the 
operated level(s) with a control level (≤ 3/10). Patients had lum-
bar dominant pain symptoms that were worse with sitting than 
with standing and had failed at least 6 months of aggressive, 
nonoperative rehabilitation and nonsurgical care. They also 
had to be willing and able to participate in the study follow-up 
regimen and complete preoperative VAS and ODI question-
naires to establish baseline scores. MRI needed to demonstrate 
Pfirrmann grade III or IV degeneration on MRI of 1 or 2 levels 
between L3 and S1. Patients were excluded if they had evidence 
of radiculopathy, symptomatic spinal stenosis, grade II or great-
er spondylolisthesis, scoliosis greater than 15 degrees, presence 
of an auto-immune disease including but not limited to rheu-
matoid arthritis, sclerodema, lupus, ankylosing spondylitis, pa-
tients taking immunosuppressive drugs or cytokine inhibitors, 
patients with prior lumbar fusion, and patients with active liti-
gation or evidence of secondary gain.
1.  Tissue Collection and Preparation of the Conditioned 
Medium
At the time of surgery, disc tissue was collected and trans-
ported in saline to the laboratory within 30 minutes of harvest 
in sterile tubes containing 25-mL phosphate-buffered saline 
(PBS) and antibiotics (penicillin 100 U/mL, streptomycin 100 
μg/mL). Annulus fibrosus and nucleus pulposis were grossly 
separated based on morphology and were washed 3 times with 
PBS and finely minced into approximately 3-mm cubes and 
were weighed in preweighed tubes with 20-mL PBS. The washed 
tissue pieces were centrifuged at 1,200 rpm for 5 minutes and 
PBS was completely removed. The washed tissue pieces were 
then cultured for 48 hours at 37°C (95% humidity) in serum-
free Opti-MEM (Gibco, by Life Technologies, Carlsbad, CA, 
USA) in 25-cm2 culture flasks with a density of 1.0 g tissue/3-
mL medium. Conditioned medium (CM) was collected after 
48-hour incubation, centrifuged at 1,200 rpm for 10 minutes, 
filtered at 0.20 µm and the supernatant was stored at -80°C un-
til further use, similar to a previously published protocol.14
2.  Cytokine Assay With Enzyme-Linked Immunosorbent 
Assay
The concentration of IL-6 in CM was quantified using en-
zyme-linked immunosorbent assays (Quantikine ELISA kits, 
R&D System, Minneapolis, MN, USA) according to the manu-
facturer’s instructions. All samples were assayed in duplicate on 
the enzyme-linked immunosorbent assay plate overnight at 4°C. 
Colorimetric absorbance was measured with a BioTek, Synergy 
HT (BioTek Instruments, Inc. Winooski, VT, USA) and ana-
lyzed with 4-parameter-logistic-curve data analysis software 
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After surgery, patients completed VAS and ODI outcomes 
questionnaires at 6 months. Demographic information for each 
patient was recorded including age and number of levels fused. 
In patients with multilevel procedures, the disc with the highest 
expression of IL-6 was used for statistical analysis. We theorized 
that the disc with the highest level of IL-6 expression would be 
the most symptomatic for the patient, and therefore the most 
representative of the patient’s dysfunction. As some discs had 
low IL-6 expression, we felt that taking an average would not 
accurately represent the patient’s level of pain and dysfunction. 
Pearson correlation coefficients (rho) were used to quantify re-
lationships between expression levels of IL-6 and preoperative 
and postoperative VAS back pain and ODI, as well as change in 
VAS back pain and ODI. Significance was assumed for p< 0.05.
 
RESULTS
Sixteen discs were harvested from 9 patients undergoing ALIF 
for discogenic pain (mean age, 47.4 years; range, 21–70 years) 
(Table 1). There were 3 revision cases in which the primary cas-
es were laminectomies without discectomies. Therefore, the 
disc tissue should not have been significantly compromised by 
the original surgery. The mean preoperative and postoperative 
(6 months) VAS back pain scores were 8.1 and 3.7 respectively. 
The mean preoperative and postoperative ODI (6 months) were 
56.2 and 25.6, respectively. There were significantly positive cor-
relations between intradiscal IL-6 expression and postoperative 
VAS back pain (ρ= 0.38, p= 0.048) and ODI (ρ= 0.44, p= 0.02). 
These findings suggest that patients with higher levels of intra-
discal IL-6 expression have more back pain and higher disabili-
ty after surgery. No significant correlations were found between 
intradiscal IL-6 expression and preoperative VAS back pain (ρ=  
Table 1. Patient demographics
Patient No. Age (yr) Sex Disc levels Positive preoperative discogram?
Decompres-
sion
Open or percutaneous 
screw placement
Primary or  
revision
1 50 Male L4–S1 Yes L5–S1 Open Primary
2 68 Female L2–4 Yes L2–4 Open Revision
3 71 Male L4–S1 Yes None Percutaneous Primary
4 22 Male L4–S1 Yes None Percutaneous Primary
5 42 Male L5–S1 Yes None Percutaneous Primary
6 47 Male L4–S1 Yes None Percutaneous Revision 
7 58 Male L4–S1 Yes None Percutaneous Revision
8 42 Female L5–S1 Yes None Percutaneous Primary
9 32 Male L2–S1 Yes None Open Primary
Table 2. Interleukin-6 expression and preoperative and postoperative outcomes
Patient No. Highest IL-6  expression (pg/mL) Level
VAS ODI
Preop Postop Delta Preop Postop Delta
1 150.55 L4–L5 8 3 5 40 22 18
2 3.82 L3–L4 9 4 5 70 28 42
3 1,248.37 L4–L5 8 6 2 68 58 10
4 536.22 L4–L5 8 6 2 50 8 42
5 43.63 L5–S1 10 0 10 46 0 46
6 438.85 L4–L5 8 4 4 66 60 6
7 246.01 L4–L5 6 3 3 50 16 34
8 478.94 L5–S1 7 3 4 58 18 40
9 818.79 L3–L4 9 4 5 58 20 38
Mean 440.58 8.11 3.67 4.44 56.22 25.56 30.67
IL-6, interleukin-6; VAS, visual analogue scale; ODI, Oswestry Disability Index; preop, preoperative; postop, postoperative.
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-0.12, p = 0.54). Trends were seen associating IL-6 expression 
and change in VAS back pain, and change in ODI (ρ = -0.35, 
p = 0.067; ρ = -0.34, p = 0.08; respectively). This suggests that 
patients with higher levels of intradiscal IL-6 expression trend-
ed towards less improvement in VAS and ODI after surgery com-
pared to those with lower IL-6 expression. Similarly, a trend was 
seen associating IL-6 expression and preoperative ODI (ρ= 0.36, 
p= 0.063) (Tables 2, 3) (Fig. 1).
DISCUSSION
This study demonstrates that patients with higher expression 
of intradiscal IL-6 have more pain and disability in the early 
postoperative period after ALIF and less pain improvement 
than those with lower expression of intradiscal IL-6. No signifi-
cant correlation could be found with intradiscal IL-6 levels and 
preoperative VAS scores. There are several possible explanations 
for this finding. First, VAS pain levels are measured at 1-time 
point, and may not accurately represent a patient’s typical pain 
over the course of time. A more accurate representation of over-
all dysfunction is seen with ODI, where trends were seen with 
IL-6 levels. While other studies have found associations with 
low back pain and cytokine levels, they compared to either non-
painful discs from surgical specimens or cadaver samples with 
no history of back pain.12,13 Our study did not have a control 
group of nonpainful discs. The Back Complaints in the Elders-
Brazil study could not find a significant correlation of several 
serum cytokine levels with “present pain intensity” and “low 
back pain frequency,”8 but found associations when models in-
cluded several other variables. This emphasizes the multifacto-
rial nature of low back pain. In addition, due to the nature of 
this study, it is not possible to have a control group of patients 
with no pain or dysfunction. If there was a control group to com-
pare to, it is possible we would find differences in preoperative 
VAS pain.
Another possible explanation for our findings is that all pa-
tients included in our study had some degree of overexpression 
of IL-6 and disc degeneration. Then, the inflammatory response 
triggered by surgery increased the pain and disability more so 
in the patients with higher intradiscal IL-6 concentration, as 
explained by their worse outcomes within the first 6 months of 
surgery. Part of the degenerative process of the disc includes in-
growth of nerves.15-17 This may be the source of exaggerated 
pain and disability in the postoperative period in those with el-
evated IL-6 levels. While the disc is removed in its entirety, the 
ingrowth of nerves from the surrounding tissues likely become 
irritated from the surgery. In addition, the chronic elevation of 
Table 3. Correlations of IL-6 with preoperative, postoperative 
and delta VAS and ODI
Outcome Correlation with IL-6 Level (ρ) p-value
Preop VAS -0.12 0.54
Postop VAS 0.38 0.048
Delta VAS -0.35 0.067
Preop ODI 0.36 0.063
Postop ODI 0.44 0.02
Delta ODI -0.34 0.08
IL-6, interleukin-6; VAS, visual analogue scale; ODI, Oswestry Dis-
ability Index; preop, preoperative; postop, postoperative.
Fig. 1. Correlations of IL-6 with preoperative, postoperative and delta VAS and ODI. IL, interleukin; VAS, visual analogue scale; 
ODI, Oswestry Disability Index.
Correlation with IL-6 level (ρ)
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IL-6 levels can cause these nerves to be hypersensitive and elicit 
an exaggerated pain response.7,18-20
Few studies have attempted to characterize the association 
between cytokine expression and clinical symptoms in a sys-
tematic manner and no studies have attempted to correlate ex-
pression of inflammatory mediators with outcome measures 
after surgical intervention. Burke et al.12 evaluated cytokine ex-
pression differences between the 2 groups of patients: those with 
discography-positive discogenic pain and those undergoing 
discectomy for sciatica secondary to herniated nucleus pulpo-
sus (HNP). Disc samples from patients with low back pain were 
found to have elevated expression of IL-6 and IL-8 compared 
with samples from patients with HNP and sciatica. However, 
postoperative outcomes were not evaluated. Using a similar 
study design, Lee et al.21 evaluated cytokine expression in pa-
tients with presumed IVD degeneration presenting with chron-
ic back pain and patients with leg-dominant symptoms with 
evidence of HNP on MRI. Groups were defined entirely on the 
basis of MRI findings of HNP and not based on clinical criteria 
or discography. They found increased expression of IL-8 in pa-
tients with greater degrees of disc degeneration and at levels 
with presumed discogenic pain as opposed to levels with HNP. 
Similarly, Le Maitre et al.22 investigated expression of IL-1β and 
associated regulatory proteins in disc tissue isolated either from 
postmortem examinations of patients with no history of back 
pain/sciatica or from patients undergoing anterior lumbar dis-
cectomy for lumbar fusion or disc replacement to treat disco-
genic back pain. This study found that IL-1β expression was 
significantly elevated in patients with discogenic back pain and 
that IL-1β was important in upregulation of other genes associ-
ated with the degenerative cascade, including degradative en-
zymes. Our study did not find a correlation of IL-6 and preop-
erative low back pain, but this may be due to not having a con-
trol group of patients with no low back pain.
Limitations to this study include a relatively small sample size 
and lack of follow-up greater than 6 months. However, there 
are only small percentage of patients that undergo surgery due 
to isolated discogenic pain, and our study had strict inclusion 
criteria. There are numerous other variables that could have 
contributed to the clinical outcomes, such as fusion rate, body 
mass index, smoking status, preoperative pain medications, med-
ical comorbidities, etc. While there is variability among the pa-
tients, including the number of levels fused, all surgeries includ-
ed an ALIF followed by posterior stabilization, and were per-
formed by the same surgeon, using the same instrumentation 
and techniques. The indication, low back pain secondary to 
disc degeneration, was consistent among all patients. Also, all 
patients had a positive preoperative discogram. In addition, 
while there was heterogeneity in the posterior techniques used, 
the disc tissue was removed during the anterior portion for all 
patients, which limits the variability that could be seen with dif-
ferent posterior fusion techniques (open versus percutaneous, 
+/- decompression). While the study design attempted to ex-
clude patients with nondiscogenic pain by performing a preop-
erative discogram, it is possible that another source of patholo-
gy contributed to pain in some patients. Based on our review of 
previous studies and those from our lab, we focused on evaluat-
ing IL-6. However as previously mentioned there are several 
other inflammatory cytokines that could more strongly corre-
late with outcomes.
Future studies will attempt to find correlations of preopera-
tive serum cytokine levels and intradiscal cytokine expression. 
If a direct correlation exists, patients that may have worse out-
comes in the earlier postoperative period could be identified 
earlier, and additional strategies for pain control or alternative 
treatments such as targeted intradiscal cytokine antibody thera-
py could be offered. However, without a preoperative test that 
correlates closely with intradiscal cytokine expression, the re-
sults are still theoretical in nature at this time.
CONCLUSION
The direct association between IL-6 expression and VAS/ODI 
suggests patients with elevated intradiscal cytokine expression 
may have worse early outcomes than those with lower expres-
sion of IL-6 after surgery for symptomatic disc degeneration.
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